Data presented at the annual American Society of Neuroimaging meeting supports clinical value and broad utility of the portable Swoop® system in outpatient neurology.
The prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI to support an FDA 510(k) submission.
Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative Growth of 54% Compared to Prior Quarter; Exiting 2025 with Approximately $35 Million of...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today...
India's Central Drugs Standard Control Organization (CDSCO) has approved the Hyperfine Swoop system, opening a major global market. Commercial launch to begin early 2026.
A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, enhancing...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop®...
Expansion of initiatives with AI-powered portable MRI will enable evaluation of childhood brain development through neonatal scanning and guide targeted health interventions in underserved communities,...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the...